Velcade Second-Line Indication Doubles Market Opportunity, Millennium Says
Approval of Millennium Pharmaceutical's Velcade (bortezomib) for second-line treatment of multiple myeloma will double the brand's current market opportunity, the company said
You may also be interested in...
A postmarketing trial assessing Velcade in previously untreated multiple myeloma patients could expand the label for the proteasome inhibitor to first-line use
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials